Illumina, Inc. is an American company that develops, manufactures and markets integrated systems for the analysis of genetic variation and biological function. Using its technologies, the Company provides a line of products and services that serve the sequencing, genotyping and gene expression markets. Illumina's customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations and biotechnology companies.

Type
Public
HQ
San Diego, US
Founded
1998
Size (employees)
6,200 (est)+13%
Illumina was founded in 1998 and is headquartered in San Diego, US
Report incorrect company information

Illumina Office Locations

Illumina has offices in Singapore, San Diego, Madison, San Francisco and in 11 other locations
San Diego, US (HQ)
5200 Illumina Way
Madison, US
200 5602 Research Park Blvd
Redwood City, US
800 Saginaw Dr
San Francisco, US
210 499 Illinois St
Santa Clara, US
210 451 El Camino Real
Scoresby, AU
1 International Ct
Show all (15)
Report incorrect company information

Illumina Financials and Metrics

Illumina Financials

Illumina's revenue was reported to be $2.40 b in FY, 2017
USD

Revenue (Q2, 2017)

662 m

Gross profit (Q2, 2017)

434 m

Gross profit margin (Q2, 2017), %

65.6%

Net income (Q2, 2017)

120 m

EBIT (Q2, 2017)

143 m

Market capitalization (20-Apr-2018)

36.2 b

Cash (7-Feb-2017)

1.2 b

EV

36.2 b
Illumina's current market capitalization is $36.2 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

1.4 b1.9 b2.2 b2.4 b2.4 b

Revenue growth, %

31%19%8%

Cost of goods sold

670.5 m731.9 m731.9 m

Gross profit

1.5 b1.7 b1.7 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017Q1, 2017Q2, 2017

Revenue

356.8 m420.8 m447.6 m480.6 m538.6 m539.4 m550.3 m607.1 m571.8 m600.1 m714 m598 m662 m

Cost of goods sold

146.9 m142.5 m147 m146.7 m163.5 m163 m162.7 m181 m174.7 m176.3 m232 m230 m228 m

Gross profit

209.9 m278.3 m300.5 m333.9 m375 m376.4 m387.5 m426.2 m397.1 m423.8 m482 m368 m434 m

Gross profit Margin, %

59%66%67%69%70%70%70%70%69%71%68%62%66%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

711.6 m636.2 m768.8 m734.5 m734.5 m

Accounts Receivable

238.9 m289.5 m385.5 m381.3 m381.3 m

Inventories

22.8 m29.8 m54.3 m77.9 m300.2 m

Current Assets

1.6 b1.9 b2.1 b2.3 b2.3 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017Q1, 2017Q2, 2017

Cash

691.8 m518.5 m675.2 m829.9 m533.5 m591.1 m551.5 m794.7 m754.9 m951.7 m1.4 b981 m1.2 b

Accounts Receivable

235.4 m293 m258.7 m276.7 m350 m368.6 m413.5 m381.6 m402.5 m372.5 m383 m368 m372 m

Inventories

159.9 m164.2 m177.5 m199.3 m205.2 m223.6 m233.8 m312.2 m287.9 m311.4 m327 m299 m309 m

Current Assets

1.5 b1.6 b1.6 b1.9 b2.1 b2.2 b2.2 b2.3 b2.1 b2.1 b2.8 b2.5 b2.6 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

125.3 m353.4 m457.4 m428.1 m428.1 m

Depreciation and Amortization

50.8 m61.9 m72.7 m90 m90 m

Inventories

1.8 m6.6 m(11 m)(1.2 m)(29.7 m)

Accounts Payable

2.4 m(2.1 m)46.3 m(2 m)(2 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q1, 2017

Net Income

31.4 m60 m46.6 m93.5 m136.7 m102.2 m115.6 m116.9 m87.2 m116.4 m348 m

Inventories

177.5 m199.3 m205.2 m223.6 m233.8 m312.2 m287.9 m311.4 m299 m

Accounts Payable

91.5 m96.1 m106.7 m107.9 m123.4 m134.1 m154.7 m250.7 m142 m
USDY, 2017

EV/EBIT

252.8 x

Revenue/Employee

120.4 k

Financial Leverage

1.8 x
Show all financial metrics
Report incorrect company information

Illumina News and Updates

Preimplantation Genetic Screening (PGS) Market Analysis 2018-2025: Illumina, PerkinElmer, CooperSurgical, BGI

The world Preimplantation Genetic Screening (PGS) market is expected to witness notable growth in the coming years owning to the rising prevalence of genetic, hereditary and chromosomal diseases. Preimplantation Genetic Screening market to profile the key players and comprehensively analyze their ma…

Loxo and Illumina in partnership over diagnostic for cancer drug

April 10 (Reuters) - Loxo Oncology is partnering with genetic testing company Illumina Inc to use Illumina's diagnostic tool alongside larotrectinib, the drug developer's potential blockbuster drug, the companies said on Tuesday.

Genomics Personalized Health Market SWOT analysis including key players QIAGEN, Illumina, Thermo Fisher Scientific

Latest research study from HTF MI with title Global Genomics Personalized Health by Manufacturers, Regions, Type and Application, Forecast to 2023. Posted via Industry Today. Follow us on Twitter @IndustryToday

Next Generation Sequencing Market By Product, Services, Application, Key Manufacturers, 2018 Global Regions Analysis and 2025 Forecasts

The Insight Partners Published “Next Generation Sequencing Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Posted via Industry Today. Follow us on Twi…
Show more
Report incorrect company information